Fig. 3: PPMI-based median prediction CIs overlayed with PASADENA median data. | Nature Medicine

Fig. 3: PPMI-based median prediction CIs overlayed with PASADENA median data.

From: Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

Fig. 3

a, MDS–UPDRS Part III OFF delayed-start group (empirical data represented in light blue). b, MDS–UPDRS Part III OFF early-start group (dark blue). c, MDS–UPDRS Part II delayed-start group (empirical data represented in light blue). d, MDS–UPDRS Part II early-start group (dark blue). Vertical red arrows indicate the start of prasinezumab treatment for both groups. Gray areas represent PPMI-based median prediction CIs.

Back to article page